Literature DB >> 15608133

Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8.

M Delaforge1, A Pruvost, L Perrin, F André.   

Abstract

In the classical metabolic oxidation scheme, hydrophobic endogenous or xenobiotic compounds undergo phase I oxidation, generally catalyzed in the liver by cytochromes P450, followed by phase II conjugation reactions, in a way that allows much more polar metabolites to be expelled from the cell through active transport mechanisms. Cytochrome P450-mediated oxidation of steroid sulfate has been described, suggesting that oxidation of polar metabolites such as glucuronide derivatives of endogenous compounds can occur. As an example, we report here that hydroxyestradiol-17beta-glucuronide can be directly formed through oxidation of estradiol-17beta-glucuronide on the aromatic C2 position. This reaction is specifically catalyzed by CYP 2C8, which is more active in female than in male human liver microsomes. A thorough docking of the molecule within the CYP 2C8 crystal structure shows that the active site is large enough to handle a glucuronide conjugate. Moreover, the most energetically favored position of the bound ligand is fully consistent with the recently published structural determinants of substrate specificity of the CYP 2C8 active site. This is the first demonstration of cytochrome P450-mediated oxidation of a steroid glucuro-conjugate. Such oxidation of a glucuronide should be a general process since, in addition to estradiol and testosterone glucuronide, it has been observed for xenobiotic compounds, e.g., diclofenac or naproxen glucuronide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15608133     DOI: 10.1124/dmd.104.002097

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

2.  Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities.

Authors:  Beibei Xu; Song Gao; Baojian Wu; Taijun Yin; Ming Hu
Journal:  J Pharm Biomed Anal       Date:  2013-08-29       Impact factor: 3.935

3.  Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid.

Authors:  Guillaume A Schoch; Jason K Yano; Stefaan Sansen; Patrick M Dansette; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2008-04-15       Impact factor: 5.157

4.  Unusual regioselectivity and active site topology of human cytochrome P450 2J2.

Authors:  Pierre Lafite; François André; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Biochemistry       Date:  2007-08-17       Impact factor: 3.162

Review 5.  Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future.

Authors:  Ian A Blair
Journal:  Steroids       Date:  2010-01-28       Impact factor: 2.668

6.  Pharmacokinetics and Metabolism of Liposome-Encapsulated 2,4,6-Trihydroxygeranylacetophenone in Rats Using High-Resolution Orbitrap Liquid Chromatography Mass Spectrometry.

Authors:  Yamen Alkhateeb; Qais Bashir Jarrar; Faridah Abas; Yaya Rukayadi; Chau Ling Tham; Yuen Kah Hay; Khozirah Shaari
Journal:  Molecules       Date:  2020-07-06       Impact factor: 4.411

7.  Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor.

Authors:  Carmen Martínez; Elena García-Martín; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez; Julián Benito-León; Isabel García-Ferrer; Pilar Vázquez-Torres; Inmaculada Puertas; José M Zurdo; Tomás López-Alburquerque; José A G Agúndez
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 4.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.